Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.33 |
| ▸ | CPB1 | P15086 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23412757 | 1.00 | CES2 (0.40) | CES2CES1CPB2CPB1TBXAS1 | |
| SCHEMBL23412684 | 0.88 | CES2 (0.40) | CES2CES1CTSK | |
| SCHEMBL23412682 | 0.88 | CES2 (0.40) | CES2CES1CTSK | |
| SCHEMBL27934340 | 0.83 | CES2 (0.41) | CES2CES1 | |
| SCHEMBL23443244 | 0.83 | CES2 (0.36) | CES2CES1CTSK | |
| SCHEMBL23443634 | 0.83 | CES2 (0.36) | CES2CES1CTSK | |
| SCHEMBL25028162 | 0.83 | CES2 (0.36) | CES2CES1CTSK | |
| SCHEMBL960617 | 0.81 | CES2 (0.41) | CES2CES1CPB2 | |
| SCHEMBL30492778 | 0.80 | CNR2 (0.40) | CES2CES1TBXAS1 | |
| SCHEMBL963394 | 0.80 | CNR2 (0.40) | CES2CES1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048657-A1 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | claimed |
| EP-4065581-A1 | PROCESS FOR THE PREPARATION (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | F. Hoffmann-La Roche AG (CH) | 2022-10-05 | — | — | EP | claimed |
| CN-114787163-A | Process for preparing (9S) -2-bromo-9- (2,3, 4-trifluorophenyl) -6,7,8, 9-tetrahydro-5H- [1,2,4] triazolo [1,5-a ] azepine | 豪夫迈·罗氏有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2021105337-A1 | PROCESS FOR THE PREPARATION (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-03 | — | — | WO | claimed |
| CN-111315745-B | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3728262-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230048657-A1 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230048657-A1 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4065581-A1 | PROCESS FOR THE PREPARATION (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | F. Hoffmann-La Roche AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-11440915-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-114787163-A | Process for preparing (9S) -2-bromo-9- (2,3, 4-trifluorophenyl) -6,7,8, 9-tetrahydro-5H- [1,2,4] triazolo [1,5-a ] azepine | 豪夫迈·罗氏有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3535266-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111315745-A | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3535266-A1 | BICYCLIC HETEROARYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048657-A1 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | APP, PSEN1, PSEN2 | CES2 1982/4885CES1 1767/4885CPB2 819/4885 |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | CES2 2899/4885CES1 2722/4885CPB2 988/4885 |
| US-11440915-B2 | Triazolo-azepine derivatives | HUWE1, PSEN1, UPF1 | CES2 2986/4885CES1 2886/4885CPB2 1185/4885 |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HUWE1, APP, HTT | CES2 2614/4885CES1 2194/4885CPB2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.